All Comments by John Hardy

  1. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1.
  2. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin.
  3. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy.
  4. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.
  5. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle.
  6. Tau is essential to beta -amyloid-induced neurotoxicity.
  7. SNP association studies in Alzheimer's disease highlight problems for complex disease analysis.
  8. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
  9. Prion protein protects human neurons against Bax-mediated apoptosis.
  10. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.
  11. tau Exon 10 expression involves a bipartite intron 10 regulatory sequence and weak 5' and 3' splice sites.
  12. Identification of a novel family of presenilin homologues.
  13. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.
  14. Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion.
  15. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.